Prognostic role of derived neutrophil-to-lymphocyte ratio in surgical triple-negative breast cancer
Authors Ren K, Yin Y, He F, Shao Y, Wang S
Received 18 July 2018
Accepted for publication 12 September 2018
Published 24 October 2018 Volume 2018:10 Pages 4891—4898
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 3
Editor who approved publication: Dr Antonella D'Anneo
Kuojun Ren,1,* Yachao Yin,2,* Fang He,3 Yi Shao,4 Shengying Wang1
1Department of Head–Neck and Breast Surgery, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of The University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, USTC, Hefei, Anhui, People’s Republic of China; 2Department of Radiotherapy, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, USTC, Hefei, Anhui, People’s Republic of China; 3Department of Respiratory Medicine, Anhui Chest Hospital, Hefei, Anhui, People’s Republic of China; 4Department of Ophthalmology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People’s Republic of China
*These authors contributed equally to this work
Introduction: The role of derived neutrophil-to-lymphocyte ratio (dNLR) in predicting the prognosis of patients with triple-negative breast cancer (TNBC) has not been well studied. Here, we attempted to investigate the significance of dNLR in predicting the prognosis of patients with surgical (nonmetastatic) TNBC.
Methods: A total of 281 patients diagnosed with surgical TNBC in The First Affiliated Hospital of University of Science and Technology of China from February 2005 to March 2015 were retrospectively included in this study. Kaplan–Meier curve analysis was used to assess the disease-free survival (DFS) and overall survival (OS). We used Cox regression model to assess the prognostic significance of pretreatment dNLR and other clinicopathological parameters in TNBC patients.
Results: The median DFS in TNBC patients who had low dNLR and high dNLR was 28.9 and 15.1 months (P<0.001), respectively, whereas the median OS in patients who had low dNLR and high dNLR was 71.2 and 42.3 months (P<0.001), respectively. In patients aged ≤50 years and with invasive ductal carcinoma, a low dNLR predicted better DFS and OS compared with a high dNLR. Multivariate analysis demonstrated that the increased dNLR was a risk factor of poor DFS (HR=1.90, 95% CI: 1.52–2.46, P=0.007) and OS (HR=2.56, 95% CI: 1.69–3.58, P=0.001).
Conclusion: Pretreatment dNLR is an independent factor of prognosis for TNBC patients, which potentially allows clinical doctors to improve outcomes of patients with high dNLR by treating with aggressive therapy, such as high-dose adjuvant chemotherapy and radiotherapy.
Keywords: dNLR, TNBC, inflammation, immunity, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]